Arbutus Biopharma Corp.

Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The company's primary focus is on advancing a portfolio of innovative therapeutics aimed at modulating the immune response to address chronic HBV infection comprehensively. Utilizing cutting-edge technologies, Arbutus develops antiviral therapies that target the virus itself while concurrently enhancing the host's immune defense. One of the core aspects of Arbutus's approach is its proprietary RNA interference (RNAi) technology used to silence specific gene expressions that contribute to the persistence of HBV. The company operates in the biotechnology sector, which plays a crucial role in global healthcare by addressing unmet medical needs through novel therapeutic developments. As part of the broader pharmaceutical and health sciences industries, Arbutus Biopharma positions itself as a leader in pioneering solutions to combat viral infections, thereby contributing significantly to public health advancements and the global effort against chronic viral illnesses.